Bullish Points: 1. Harrow Health specializes in ophthalmic-focused pharmaceuticals and owns the U.S. commercial rights to ten branded products. 2. The company has made significant acquisitions, such as IHEEZO and MAQ-100, expanding its product portfolio. 3. Harrow Health has ownership interests in Surface, Melt, and Eton Pharmaceuticals, and royalty interests in some of their drug candidates. 4. Successful clinical trials for MELT-300 and SURF-100, with Harrow Health owning significant equity in both Melt and Surface. 5. Revenues for the year ended December 31, 2022, increased by $16,119,000 compared to 2021. Bearish Points: 1. Accumulated deficit as of December 31, 2022: $(109,493,000). 2. The company has limited experience in operating pharmacies and commercializing compounded formulatio

Bullish Points: 1. Total revenues for the three months ended March 31, 2023 increased to $26,103,000 compared to $22,120,000 in 2022. 2. Gross Profit for the three months ended March 31, 2023 increased to $17,832,000 compared to $16,157,000 in 2022. 3. Acquisition of five ophthalmic products from Novartis for a one-time payment of $130,000,000 in January 2023. 4. IHEEZO received a permanent, product-specific J-code for reimbursement purposes, and its full commercial launch occurred in May 2023. Bearish Points: 1. Net loss for the three months ended March 31, 2023 increased to $6,643,000 compared to $2,438,000 in 2022. 2. Gross Margin decreased by 4.7% between the three months ended March 31, 2023, and 2022. 3. Cash and cash equivalents at the end of the period (March 31, 2023) decreased to